Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: A phase I and pharmacokinetic study in patients with advanced cancer

A. H G Hansma, H. J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H. M. Pinedo, K. Hoekman

Research output: Contribution to journalArticle

Abstract

Background: Endostatin is an endogenous collagen XVIII-fragment with anti-angiogenic properties and remarkable antitumor activity in mice. Preclinical data suggest that continuous low dose administration of endostatin is much more potent than intermittent dosing. The feasibility of this approach is tested in a phase I study. Patients and methods: We determined the safety and pharmacokinetic profile of 4-week continuous intravenous infusion of recombinant human (rh)-endostatin, followed after an interval of 1 week by twice daily subcutaneous injections in patients with advanced cancer. Thirty-two patients received rh-endostatin in six dosing cohorts, ranging from 3.75 mg/m2/day to 120 mg/m2/day. Serum endostatin pharmacokinetics, toxicity and antitumor response were determined. Results: A total of 160 cycles were delivered without significant toxicities. Pharmacokinetic analysis showed a linear increase of steady-state serum endostatin concentrations with dose (i.v. r2= 0.96; s.c. r2 = 0.99) reaching 300-1000 ng/ml for the two highest doses, with considerable interpatient variation. The main pharmacokinetic values for both routes of administration were similar. The apparent steady-state concentration and AUC reached at 60 = 120 mg/m2/day were within the range expected to induce anti-angiogenic and antitumor effects based on preclinical tumor models. Although no objective responses were observed, two patients had long-lasting stable disease (defined as a tumor increase <100%). Conclusion: rh-endostatin was safely administered both by continuous infusion and by twice daily subcutaneous injections up to 120 mg/m2/day. Predictable pK was seen in this dose range and the target endostatin levels were reached from 60 mg/m2/day and above.

Original languageEnglish (US)
Pages (from-to)1695-1701
Number of pages7
JournalAnnals of Oncology
Volume16
Issue number10
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Endostatins
Subcutaneous Injections
Intravenous Infusions
Pharmacokinetics
Neoplasms
Collagen Type XVIII
Serum
Area Under Curve
Safety

Keywords

  • Angiogenesis
  • Endostatin
  • Pharmacokinetics
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections : A phase I and pharmacokinetic study in patients with advanced cancer. / Hansma, A. H G; Broxterman, H. J.; van der Horst, I.; Yuana, Y.; Boven, E.; Giaccone, G.; Pinedo, H. M.; Hoekman, K.

In: Annals of Oncology, Vol. 16, No. 10, 10.2005, p. 1695-1701.

Research output: Contribution to journalArticle

Hansma, A. H G ; Broxterman, H. J. ; van der Horst, I. ; Yuana, Y. ; Boven, E. ; Giaccone, G. ; Pinedo, H. M. ; Hoekman, K. / Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections : A phase I and pharmacokinetic study in patients with advanced cancer. In: Annals of Oncology. 2005 ; Vol. 16, No. 10. pp. 1695-1701.
@article{9822bf7951114af8a11095e615f05bd3,
title = "Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: A phase I and pharmacokinetic study in patients with advanced cancer",
abstract = "Background: Endostatin is an endogenous collagen XVIII-fragment with anti-angiogenic properties and remarkable antitumor activity in mice. Preclinical data suggest that continuous low dose administration of endostatin is much more potent than intermittent dosing. The feasibility of this approach is tested in a phase I study. Patients and methods: We determined the safety and pharmacokinetic profile of 4-week continuous intravenous infusion of recombinant human (rh)-endostatin, followed after an interval of 1 week by twice daily subcutaneous injections in patients with advanced cancer. Thirty-two patients received rh-endostatin in six dosing cohorts, ranging from 3.75 mg/m2/day to 120 mg/m2/day. Serum endostatin pharmacokinetics, toxicity and antitumor response were determined. Results: A total of 160 cycles were delivered without significant toxicities. Pharmacokinetic analysis showed a linear increase of steady-state serum endostatin concentrations with dose (i.v. r2= 0.96; s.c. r2 = 0.99) reaching 300-1000 ng/ml for the two highest doses, with considerable interpatient variation. The main pharmacokinetic values for both routes of administration were similar. The apparent steady-state concentration and AUC reached at 60 = 120 mg/m2/day were within the range expected to induce anti-angiogenic and antitumor effects based on preclinical tumor models. Although no objective responses were observed, two patients had long-lasting stable disease (defined as a tumor increase <100{\%}). Conclusion: rh-endostatin was safely administered both by continuous infusion and by twice daily subcutaneous injections up to 120 mg/m2/day. Predictable pK was seen in this dose range and the target endostatin levels were reached from 60 mg/m2/day and above.",
keywords = "Angiogenesis, Endostatin, Pharmacokinetics, Phase I",
author = "Hansma, {A. H G} and Broxterman, {H. J.} and {van der Horst}, I. and Y. Yuana and E. Boven and G. Giaccone and Pinedo, {H. M.} and K. Hoekman",
year = "2005",
month = "10",
doi = "10.1093/annonc/mdi318",
language = "English (US)",
volume = "16",
pages = "1695--1701",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections

T2 - A phase I and pharmacokinetic study in patients with advanced cancer

AU - Hansma, A. H G

AU - Broxterman, H. J.

AU - van der Horst, I.

AU - Yuana, Y.

AU - Boven, E.

AU - Giaccone, G.

AU - Pinedo, H. M.

AU - Hoekman, K.

PY - 2005/10

Y1 - 2005/10

N2 - Background: Endostatin is an endogenous collagen XVIII-fragment with anti-angiogenic properties and remarkable antitumor activity in mice. Preclinical data suggest that continuous low dose administration of endostatin is much more potent than intermittent dosing. The feasibility of this approach is tested in a phase I study. Patients and methods: We determined the safety and pharmacokinetic profile of 4-week continuous intravenous infusion of recombinant human (rh)-endostatin, followed after an interval of 1 week by twice daily subcutaneous injections in patients with advanced cancer. Thirty-two patients received rh-endostatin in six dosing cohorts, ranging from 3.75 mg/m2/day to 120 mg/m2/day. Serum endostatin pharmacokinetics, toxicity and antitumor response were determined. Results: A total of 160 cycles were delivered without significant toxicities. Pharmacokinetic analysis showed a linear increase of steady-state serum endostatin concentrations with dose (i.v. r2= 0.96; s.c. r2 = 0.99) reaching 300-1000 ng/ml for the two highest doses, with considerable interpatient variation. The main pharmacokinetic values for both routes of administration were similar. The apparent steady-state concentration and AUC reached at 60 = 120 mg/m2/day were within the range expected to induce anti-angiogenic and antitumor effects based on preclinical tumor models. Although no objective responses were observed, two patients had long-lasting stable disease (defined as a tumor increase <100%). Conclusion: rh-endostatin was safely administered both by continuous infusion and by twice daily subcutaneous injections up to 120 mg/m2/day. Predictable pK was seen in this dose range and the target endostatin levels were reached from 60 mg/m2/day and above.

AB - Background: Endostatin is an endogenous collagen XVIII-fragment with anti-angiogenic properties and remarkable antitumor activity in mice. Preclinical data suggest that continuous low dose administration of endostatin is much more potent than intermittent dosing. The feasibility of this approach is tested in a phase I study. Patients and methods: We determined the safety and pharmacokinetic profile of 4-week continuous intravenous infusion of recombinant human (rh)-endostatin, followed after an interval of 1 week by twice daily subcutaneous injections in patients with advanced cancer. Thirty-two patients received rh-endostatin in six dosing cohorts, ranging from 3.75 mg/m2/day to 120 mg/m2/day. Serum endostatin pharmacokinetics, toxicity and antitumor response were determined. Results: A total of 160 cycles were delivered without significant toxicities. Pharmacokinetic analysis showed a linear increase of steady-state serum endostatin concentrations with dose (i.v. r2= 0.96; s.c. r2 = 0.99) reaching 300-1000 ng/ml for the two highest doses, with considerable interpatient variation. The main pharmacokinetic values for both routes of administration were similar. The apparent steady-state concentration and AUC reached at 60 = 120 mg/m2/day were within the range expected to induce anti-angiogenic and antitumor effects based on preclinical tumor models. Although no objective responses were observed, two patients had long-lasting stable disease (defined as a tumor increase <100%). Conclusion: rh-endostatin was safely administered both by continuous infusion and by twice daily subcutaneous injections up to 120 mg/m2/day. Predictable pK was seen in this dose range and the target endostatin levels were reached from 60 mg/m2/day and above.

KW - Angiogenesis

KW - Endostatin

KW - Pharmacokinetics

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=26844512403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844512403&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi318

DO - 10.1093/annonc/mdi318

M3 - Article

C2 - 16012180

AN - SCOPUS:26844512403

VL - 16

SP - 1695

EP - 1701

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -